What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q4 Earnings

Core Viewpoint - Teva Pharmaceutical Industries Ltd. (TEVA) is expected to report a quarterly earnings per share (EPS) of $0.64, reflecting a year-over-year decline of 9.9%, while revenues are anticipated to reach $4.34 billion, showing a 2.6% increase compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised 2.2% lower over the last 30 days, indicating a reevaluation by analysts [2]. - Revisions to earnings estimates are significant indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock price performance [3]. Revenue Projections - Analysts forecast 'Revenue- API sales to third parties' to reach $154.37 million, indicating a 6.5% increase year-over-year [5]. - 'Revenue- COPAXONE- Total' is expected to be $63.50 million, reflecting a substantial decline of 48% year-over-year [5]. - 'Geographic Revenue- United States' is projected at $2.15 billion, suggesting an 8.6% increase year-over-year [5]. - 'Geographic Revenue- Europe' is estimated to be $1.32 billion, indicating a decrease of 2.7% from the prior year [6]. - 'Geographic Revenue- International Markets' is expected to be $625.03 million, reflecting a decline of 5.4% year-over-year [6]. Specific Revenue Metrics - 'Geographic Revenue- Europe- Respiratory products' is estimated at $57.29 million, down 6.1% from the previous year [7]. - 'Geographic Revenue- International Markets- Generic products' is projected at $446.04 million, indicating a decline of 10.3% year-over-year [7]. - 'Geographic Revenue- International Markets- COPAXONE' is expected to reach $5.14 million, reflecting a significant drop of 42.9% from the prior year [8]. - 'Geographic Revenue- United States- AJOVY' is projected at $70.98 million, indicating a year-over-year increase of 12.7% [8]. - 'Geographic Revenue- Europe- Generic products' is expected to be $1.01 billion, reflecting a 2.9% increase year-over-year [9]. - 'Geographic Revenue- Europe- AJOVY' is projected at $74.75 million, indicating a substantial increase of 28.9% from the prior year [9]. - 'Geographic Revenue- Europe- Other' is estimated at $168.65 million, reflecting a decline of 17.7% from the previous year [9]. Stock Performance - Teva's shares have shown a return of -0.3% over the past month, compared to a +0.6% change in the Zacks S&P 500 composite [10].